Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease by Gabriel L Ketron, Felix Grun, Joshua D Grill, Howard H Feldman, Robert A Rissman, Gregory J Brewer

Get full text

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomat... by Jeffrey L. Cummings, Alireza Atri, Howard H. Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, Peter Johannsen, Teresa León, Philip Scheltens

Get full text

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 by Branislav Kovacech, Nicholas C. Cullen, Petr Novak, Jozef Hanes, Eva Kontsekova, Stanislav Katina, Vojtech Parrak, Michal Fresser, Jeroen Vanbrabant, Howard H. Feldman, Bengt Winblad, Erik Stoops, Eugeen Vanmechelen, Norbert Zilka

Get full text

Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease by Yuqi Qiu, Diane M. Jacobs, Karen Messer, David P. Salmon, Cheryl L. Wellington, Sophie Stukas, Carolyn Revta, James B. Brewer, Gabriel C. Léger, Brianna Askew, Lia Donahue, Stephen Kaplita, Vladimir Coric, Irfan A. Qureshi, Howard H. Feldman, The Alzheimer’s Disease Cooperative Study T2 Protect AD Study Group

Get full text

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's di... by Howard H Feldman, José A Luchsinger, Gabriel C Léger, Curtis Taylor, Diane M Jacobs, David P Salmon, Steven D Edland, Karen Messer, Carolyn Revta, Sarah A Flowers, Kerry S Jones, Albert Koulman, Kevin E Yarasheski, Philip B Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, Gary E Gibson, ADCS BenfoTeam Study Group

Get full text